Connect
MJA
MJA

Joining the dots for the management of clinically severe obesity

John B Dixon
Med J Aust 2015; 202 (9): . || doi: 10.5694/mja14.01753
Published online: 18 May 2015

Perceptions about the cause, prevention and management of obesity need to change

At its annual meeting in June 2013, the American Medical Association (AMA) adopted a policy that recognised obesity as “a disease requiring a range of medical interventions to advance … prevention and management”.1 On the first anniversary of this decision, with the firm support of relevant colleges and associations, the AMA went further by adopting a policy that supported patient access to the full spectrum of evidence-based obesity interventions, including behavioural, pharmaceutical, psychosocial, nutritional, pharmacological and surgical options.2 The next steps in delivering better integrated care in the United States will not be easy, as they will not only require a transformational change to health services, but also that community perceptions of obesity be confronted. These steps will need to recognise and manage clinically severe obesity (ie, significant health impairment, including comorbid conditions and functional status directly related to excess weight, regardless of whether body mass index [BMI] exceeds 35 kg/m2) as a chronic disease.3 We have already seen that incremental changes in health care service delivery, chronic disease models of care, and the widespread use of effective interventions have delivered markedly improved outcomes for people with type 2 diabetes in many countries.4 This experience provides a template for delivering better health outcomes for those with clinically severe obesity.


  • Baker IDI Heart and Diabetes Institute, Melbourne, VIC.


Correspondence: John.Dixon@bakeridi.edu.au

Acknowledgements: 

I receive research support from the National Health and Medical Research Council as a Senior Research Fellow.

Competing interests:

I have consultancies with Apollo Endosurgery and Bariatric Advantage, serve on scientific advisory boards for Nestlé Australia and Novo Nordisk, have received speaker's fees from Eli Lilly, Biogen Idec, Abbott Australasia and iNova Pharmaceuticals. My research institute has received funding from Nestlé Australia, Allergan and BUPA.

  • 1. American Medical Association. AMA adopts new policies on second day of voting at annual meeting [media release]. 18 Jun 2013. http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page (accessed Aug 2014).
  • 2. Smith SR, The Obesity Society. AMA joins call for coverage of obesity treatments and medications [media release]. 2014. http://www.obesity.org/news-center/ama-joins-call-for-coverage-of-obesity-treatments-and-medications.htm (accessed Aug 2014).
  • 3. Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ 2011; 183: E1059-E1066.
  • 4. Gregg EW, Cheng YJ, Saydah S, et al. Trends in death rates among US adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care 2012; 35: 1252-1257.
  • 5. Royal College of Physicians. Action on obesity: comprehensive care for all. Report of a working party. January 2013. https://www.rcplondon.ac.uk/sites/default/files/action-on-obesity.pdf (accessed Apr 2014).
  • 6. Royal College of Surgeons of England, British Obesity and Metabolic Surgery Society. Commissioning guide: weight assessment and management clinics (tier 3). London: RCS, 2014.
  • 7. Public Health England Obesity and Healthy Weight Team, NHS England. Report of the working group into: joined up clinical pathways for obesity. NHS England, 2014. http://www.england.nhs.uk/wp-content/uploads/2014/03/owg-join-clinc-path.pdf (accessed Apr 2015).
  • 8. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154.
  • 9. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-530.
  • 10. Dixon JB, Hayden MJ, O'Brien PE, Piterman L. Physician attitudes, beliefs and barriers towards the management and treatment of adult obesity: a literature review. Aust J Prim Health 2008; 14: 9-18.
  • 11. Walls HL, Magliano DJ, Stevenson CE, et al. Projected progression of the prevalence of obesity in Australia. Obesity (Silver Spring) 2012; 20: 872-878.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.